In the following video, Motley Fool health care analyst David Williamson talks about Pfizer's (NYSE:PFE) earnings report. He details how the company managed to cut costs and shore up emerging market sales -- leading to it beating expectations this quarter -- despite the loss of patent protection for its cardiovascular disease prevention drug Lipitor, which was once the greatest-selling drug of all time.